This approach resulted in a 45% reduction in the likelihood of progressing to stage C HF and left ventricular dysfunction compared to the usual primary care group.In the PONTIAC trial, patients with T2DM at high risk for HF and NT-proBNP levels ≥ 125 pg/mL benefitted from intensified neurohormonal blockade therapy and cardiovascular disease specialist care, reducing the risk of subsequent HF by 65% (83). The gene discussed is NPPB; the disease is hydrops fetalis.